THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [4.10] ID: TIP-MED-000054

Canagliflozin

Active Ingredient / Scientific Identity: Canagliflozin • Class: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (with Mild Intestinal SGLT1 Inhibition)

⚖️ Compare Profile
Generic / Entity NameCanagliflozin ([4.10])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassSodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (with Mild Intestinal SGLT1 Inhibition)
Available Dosage FormsOral Film-Coated Tablets: 100 mg, 300 mg
Regulatory ClassificationSchedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this pre
Key Warning & Review DateRenal: Strictly renal-function dependent! • eGFR ≥60 mL/min: 100 mg or 300 mg OD. • eGFR 30 to <60 mL/min: Limit to 100 mg on
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H & Schedule G Prescription Drug ('Caution:✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Canagliflozin (TIP-MED-000054, Reference Code [4.10]) is classified under Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (with Mild Intestinal SGLT1 Inhibition). Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.10], p. 49): Invokana (Janssen), Sulisent (USV), Prominad — Strengths & Dosage Forms: Oral Film-Coated Tablets: 100 mg, 300 mg
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.10], p. 49): Invokana (Janssen), Sulisent (USV), Prominad — Strengths & Dosage Forms: Oral Film-Coated Tablets: 100 mg, 300 mg
Dosage Forms & Available Strengths:
Oral Film-Coated Tablets: 100 mg, 300 mg
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (with Mild Intestinal SGLT1 Inhibition) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor (with Mild Intestinal SGLT1 Inhibition) for Type 2 diabetes mellitus; reduction of major adverse cardiovascular events and progression of diabetic nephropathy (diabetic kidney disease with albuminuria)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Type 2 diabetes mellitus
  • reduction of major adverse cardiovascular events and progression of diabetic nephropathy (diabetic kidney disease with albuminuria)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Initially 100 mg once daily before the first meal; may increase to 300 mg once daily in patients with eGFR ≥60 mL/min requiring additional glycaemic control. If eGFR 30 to <60 mL/min: maximum 100 mg once daily. Follow physician prescription.

Administration & Meal Timing: Take BEFORE the first meal of the day (Breakfast)—taking before breakfast allows transient local intestinal SGLT1 inhibition in the gut lumen to blunt postprandial glucose excursion. | Once daily in the morning before breakfast.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Strictly renal-function dependent! • eGFR ≥60 mL/min: 100 mg or 300 mg OD. • eGFR 30 to <60 mL/min: Limit to 100 mg once daily. • eGFR <30 mL/min: Do not initiate; however, in patients with albuminuria >300 mg/day already taking 100 mg OD, may continue 100 mg OD for renoprotection until dialysis. Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
Elimination & Renal Adjustment:
Renal: Strictly renal-function dependent! • eGFR ≥60 mL/min: 100 mg or 300 mg OD. • eGFR 30 to <60 mL/min: Limit to 100 mg once daily. • eGFR <30 mL/min: Do not initiate; however, in patients with albuminuria >300 mg/day already taking 100 mg OD, may continue 100 mg OD for renoprotection until dialysis. Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).
Hepatic Impairment Considerations:
Renal: Strictly renal-function dependent! • eGFR ≥60 mL/min: 100 mg or 300 mg OD. • eGFR 30 to <60 mL/min: Limit to 100 mg once daily. • eGFR <30 mL/min: Do not initiate; however, in patients with albuminuria >300 mg/day already taking 100 mg OD, may continue 100 mg OD for renoprotection until dialysis. Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in Type 1 DM, DKA, and dialysis. Specific Warnings: Increased risk of lower-limb amputation (mostly toe/metatarsal in patients with prior amputation, severe PAD, diabetic foot ulcer, or neuropathy) and bone fractures (via decreased bone mineral density and volume-depletion falls). Hold 3 days before major surgery.

Key Clinical Precautions: Renal: Strictly renal-function dependent! • eGFR ≥60 mL/min: 100 mg or 300 mg OD. • eGFR 30 to <60 mL/min: Limit to 100 mg once daily. • eGFR <30 mL/min: Do not initiate; however, in patients with albuminuria >300 mg/day already taking 100 mg OD, may continue 100 mg OD for renoprotection until dialysis. Hepatic: Avoid in severe hepatic impairment (Child-Pugh C).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Genital fungal infections, UTI, osmotic diuresis, postural dizziness, constipation, mild hyperkalaemia (especially at 300 mg or in moderate CKD with RAAS blockers).
  • Lower-limb amputation / diabetic foot gangrene, euglycaemic DKA, Fournier's gangrene, bone fractures, acute kidney injury.
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • UGT enzyme inducers (rifampicin, phenytoin, carbamazepine, phenobarbitone) decrease canagliflozin exposure—increase dose to 300 mg if eGFR ≥60 mL/min or use alternative
  • Increases serum digoxin Cmax by 36% (monitor digoxin)
  • Additive hypotension with loop diuretics

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Instruct patients to inspect their feet daily for blisters, cuts, redness, or ulcers, never walk barefoot indoors or at temples, and wear protective diabetic footwear. Practice water-washing hygiene after every urination.
  • Meal & Clock Timing Instruction: Take BEFORE the first meal of the day (Breakfast)—taking before breakfast allows transient local intestinal SGLT1 inhibition in the gut lumen to blunt postprandial glucose excursion. (Once daily in the morning before breakfast.)
  • Missed Dose Protocol: Take as soon as remembered in the morning/early afternoon; skip if remembered in the evening.
  • Geriatric Dispensing Pearl: Use with heightened caution in elderly patients with osteoporosis, fall history, peripheral vascular disease, or diabetic neuropathy; empagliflozin or dapagliflozin is often preferred if amputation or fracture risk is elevated.

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Film-Coated Tablets: 100 mg, 300 mg

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.10] (p. 49)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.